Psilocybin vs SSRIs: What the Head-to-Head Trial Actually Found

The Trial That Changed the Conversation

In April 2021, researchers at Imperial College London published the results of the first randomised controlled trial to directly compare psilocybin therapy against a selective serotonin reuptake inhibitor (SSRI) — specifically escitalopram (sold as Lexapro or Cipralex). The study, published in the New England Journal of Medicine, enrolled 59 patients with moderate-to-severe major depressive disorder and ran for six weeks [Carhart-Harris et al., 2021].

The headline finding: psilocybin therapy was comparable to escitalopram on the primary outcome measure (the Quick Inventory of Depressive Symptomatology, or QIDS). But the secondary findings told a more nuanced story — and they are the reason this trial has been cited over 1,700 times since publication [Carhart-Harris et al., 2021].

This landmark study marked a significant shift in psychiatric research. For decades, SSRIs have been the first-line pharmacological treatment for depression. While effective for many, they are not a panacea. A substantial portion of patients do not respond adequately, and many who do experience significant side effects. The Imperial trial was designed not just to see if psilocybin worked, but to see how it stacked up against the current standard of care in a rigorous, head-to-head comparison.

What the Numbers Actually Showed

On the QIDS primary measure, both groups showed significant improvement. The psilocybin group showed a mean reduction of 8.0 points; the escitalopram group showed 6.0 points. The difference was not statistically significantly (the trial was not powered to show superiority), but the effect size favoured psilocybin [Carhart-Harris et al., 2021].

On secondary measures, the differences were more pronounced:

• Wellbeing (WEMWBS scale): Psilocybin group improved by 7.6 points vs 4.9 for escitalopram [Carhart-Harris et al., 2021].
• Anhedonia (SHAPS scale): Psilocybin group showed significantly greater reduction in inability to feel pleasure [Carhart-Harris et al., 2021].
• Psychological connectedness: Psilocybin group showed significantly greater improvements in sense of meaning and purpose [Carhart-Harris et al., 2021].
• Emotional processing: Psilocybin group showed increased emotional range; escitalopram group showed emotional blunting [Carhart-Harris et al., 2021].

Detailed Comparison of Outcomes

To fully grasp the implications of the trial, it is helpful to look at the specific data points across various measures. The following table summarizes key findings from the study.

The emotional blunting finding is particularly significant. SSRIs are known to produce emotional blunting in a substantial proportion of patients — a flattening of both negative and positive emotions that many patients describe as worse than the depression itself [Opbroek et al., 2002]. The psilocybin group showed the opposite effect: increased emotional range and greater access to positive emotions. This distinction is crucial for patient quality of life and long-term recovery.

The Mechanism Difference: How They Work in the Brain

SSRIs work by increasing serotonin availability in the synaptic cleft — a blunt instrument that affects all serotonin-dependent processes simultaneously. The result is a gradual, generalised shift in mood that takes 4–6 weeks to manifest and requires daily dosing to maintain [Trivedi et al., 2006].

Psilocybin works differently. It binds directly to serotonin 2A receptors — particularly in the prefrontal cortex and default mode network — producing a temporary but profound shift in brain network connectivity [Carhart-Harris et al., 2017]. The 2022 fMRI study by Daws et al. in Nature Medicine showed that psilocybin therapy produced lasting increases in brain network flexibility that correlated directly with antidepressant response [Daws et al., 2022]. This flexibility — the brain's ability to shift between different functional states — is precisely what depression reduces.

The key implication: SSRIs manage symptoms through continuous pharmacological intervention. Psilocybin appears to produce a reset — a change in the underlying network architecture that persists after the drug has cleared the system. This "reset" mechanism is thought to be responsible for the rapid onset of antidepressant effects seen with psilocybin, often occurring within days of a single dose, compared to the weeks required for SSRIs to take effect.

Neuroplasticity and the Default Mode Network

Further research into the mechanisms of psilocybin highlights its role in promoting neuroplasticity. Studies have shown that psychedelics can promote structural and functional neural plasticity, essentially helping the brain to rewire itself [Ly et al., 2018]. This is particularly relevant in depression, which is often characterized by rigid, negative thought patterns associated with an overactive Default Mode Network (DMN). Psilocybin has been shown to decrease DMN activity during the acute experience, followed by a "reboot" that allows for more flexible thinking and a break from depressive rumination [Carhart-Harris et al., 2017]. For more on this, see our article on how psilocybin rewires the brain.

What This Means for People Who've Tried Antidepressants

Approximately 30–40% of people with major depression do not respond adequately to first-line antidepressant treatment [Rush et al., 2006]. For this group — classified as treatment-resistant depression — the Imperial trial is particularly relevant. The psilocybin group in the trial included patients who had previously tried antidepressants without adequate response, and the effect sizes in this subgroup were at least as strong as in the overall population.

The practical implication: for people who have tried SSRIs and found them either ineffective or intolerable (due to side effects including emotional blunting, sexual dysfunction, or weight gain), psilocybin therapy represents a mechanistically distinct alternative with a different — and in some respects more favourable — side effect profile. While SSRIs often require ongoing daily use, psilocybin therapy typically involves only one or two dosing sessions accompanied by psychological support, potentially offering long-lasting relief without the burden of daily medication.

Addressing the Side Effect Profile

When comparing treatments, the side effect profile is as important as efficacy. SSRIs are commonly associated with sexual dysfunction, weight gain, insomnia, and the aforementioned emotional blunting. In contrast, the adverse events reported in the psilocybin trial were generally mild and transient, such as headache, nausea, and transient anxiety during the dosing session [Carhart-Harris et al., 2021]. Importantly, psilocybin does not appear to cause the sexual dysfunction or emotional blunting characteristic of SSRIs, making it a potentially more tolerable option for many patients.

The Microdosing Bridge

For people who cannot access clinical psilocybin therapy, microdosing offers a sub-threshold approach that engages the same serotonin 2A receptor system without the full psychedelic experience. The 2021 Scientific Reports observational study found microdosers reported significantly lower depression and anxiety scores compared to non-microdosing controls, with improvements in emotional regulation and psychological wellbeing that parallel the secondary outcomes of the Imperial trial [Rootman et al., 2021].

The standard protocol is 100–150mg psilocybin on a 4-on, 3-off schedule. Unlike SSRIs, microdosing does not require daily dosing to maintain effect — the rest days are built into the protocol to prevent receptor tolerance. Many individuals turn to microdosing as a way to manage symptoms without the side effects of traditional antidepressants. If you are considering this approach, you can learn more about how to start microdosing psilocybin safely and effectively.

Microdosing vs. Macrodosing

It is important to distinguish between the high-dose (macrodose) therapy used in the Imperial trial and the practice of microdosing. While the trial used doses of 25mg to induce a profound psychedelic experience, microdosing involves taking roughly one-tenth of that amount — enough to potentially stimulate neuroplasticity and mood improvements without causing hallucinations or significant alterations in consciousness. Both approaches show promise, but they serve different needs and require different protocols. For a deeper dive into the differences, explore our comparison of microdosing vs antidepressants side effects.

The Role of Psychological Support

A critical component of the Imperial trial, and psilocybin therapy in general, is the inclusion of psychological support. Unlike SSRIs, which are typically prescribed with minimal psychological intervention, psilocybin was administered in a carefully controlled setting with trained therapists present before, during, and after the dosing sessions [Carhart-Harris et al., 2021]. This "set and setting" is believed to be essential for maximizing the therapeutic benefits and minimizing risks. The therapy helps patients integrate the insights gained during the psychedelic experience into their daily lives, contributing to the long-lasting effects observed in the study.

Future Directions and Ongoing Research

While the results of the Imperial trial are highly encouraging, they are not the final word. The study was relatively small (59 participants) and lasted only six weeks. Larger, multi-center phase 3 trials are currently underway to further evaluate the safety and efficacy of psilocybin for depression over longer periods. These trials will be crucial for determining whether psilocybin can gain regulatory approval as a mainstream medical treatment.

At Shrooomz, we are closely monitoring these developments. We believe in the power of functional and psychedelic mushrooms to support mental health and well-being. Whether you are exploring the cognitive benefits of Lion's Mane or the potential of microdosing, Happy Shrooomz is committed to providing science-backed information and high-quality products to support your journey.

Conclusion

The head-to-head trial comparing psilocybin to escitalopram represents a watershed moment in mental health research. While both treatments reduced depressive symptoms, psilocybin's superiority in secondary outcomes — particularly its ability to enhance emotional connection rather than blunt it — highlights its potential as a transformative therapy. As research continues to unfold, psilocybin may soon offer a vital new option for the millions of people worldwide who struggle with depression and have not found relief with traditional antidepressants.

Frequently Asked Questions (FAQ)

Understanding Treatment-Resistant Depression

To fully appreciate the significance of the psilocybin vs. escitalopram trial, it is important to understand the context of treatment-resistant depression (TRD). TRD is typically defined as a major depressive episode that has not responded adequately to at least two different antidepressant trials of adequate dose and duration. It is a severe and debilitating condition that affects a significant portion of the depressed population. Patients with TRD often experience more severe symptoms, higher rates of comorbid psychiatric and medical conditions, and a greater risk of suicide compared to those with non-resistant depression.

For decades, the options for TRD have been limited. Strategies often involve switching to a different class of antidepressant, adding an augmenting agent (such as an atypical antipsychotic or lithium), or utilizing somatic therapies like electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS). While these approaches can be effective for some, they often come with significant side effects and varying success rates. The emergence of psilocybin as a potential treatment for TRD offers a beacon of hope for a patient population that has historically been very difficult to treat.

The Role of the Serotonin 2A Receptor

The pharmacological differences between SSRIs and psilocybin center largely on their interaction with the serotonin system, specifically the 5-HT2A receptor. SSRIs, as their name suggests, inhibit the reuptake of serotonin, leading to an overall increase in serotonin levels in the brain. This broad increase affects multiple serotonin receptor subtypes, which contributes to both their therapeutic effects and their side effects.

Psilocybin, on the other hand, is a classic psychedelic that acts primarily as an agonist (activator) at the 5-HT2A receptor. This specific receptor is highly concentrated in areas of the brain associated with high-level cognitive function, such as the prefrontal cortex. Activation of the 5-HT2A receptor by psilocybin is believed to be the primary trigger for the profound alterations in consciousness, perception, and emotion that characterize the psychedelic experience. More importantly for its therapeutic potential, this activation is also thought to initiate the cascade of neurobiological events that lead to increased neuroplasticity and the "resetting" of brain networks implicated in depression.

Safety and Tolerability: A Closer Look

In the Imperial College trial, both psilocybin and escitalopram were generally well-tolerated, but their side effect profiles differed significantly. The most common adverse events in the escitalopram group were those typically associated with SSRIs: headache, nausea, fatigue, and sexual dysfunction. These side effects often persist for the duration of treatment and can be a major reason why patients discontinue their medication.

In the psilocybin group, the most common adverse events were headache, nausea, and transient anxiety. Crucially, these side effects were almost entirely confined to the dosing days and the immediate aftermath. Once the acute effects of the drug wore off, patients generally did not experience ongoing side effects. Furthermore, psilocybin did not cause the sexual dysfunction or emotional blunting that are common with SSRIs. This difference in tolerability is a major factor in the growing interest in psilocybin as a preferred treatment option for some patients.

References

• [Carhart-Harris et al., 2021] Carhart-Harris, R., Giribaldi, B., Watts, R., et al. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402-1411. Link
• [Opbroek et al., 2002] Opbroek, A., Delgado, P. L., Laukes, C., et al. (2002). Emotional blunting associated with SSRI-induced sexual dysfunction: do SSRIs inhibit emotional responses? International Journal of Neuropsychopharmacology, 5(2), 147-151. Link
• [Trivedi et al., 2006] Trivedi, M. H., Rush, A. J., Wisniewski, S. R., et al. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry, 163(1), 28-40. Link
• [Carhart-Harris et al., 2017] Carhart-Harris, R. L., Roseman, L., Bolstridge, M., et al. (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific Reports, 7(1), 13187. Link
• [Daws et al., 2022] Daws, R. E., Timmermann, C., Giribaldi, B., et al. (2022). Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine, 28(4), 845-853. Link
• [Ly et al., 2018] Ly, C., Greb, A. C., Cameron, L. P., et al. (2018). Psychedelics promote structural and functional neural plasticity. Cell Reports, 23(11), 3170-3182. Link
• [Rush et al., 2006] Rush, A. J., Trivedi, M. H., Wisniewski, S. R., et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry, 163(11), 1905-1917. Link
• [Rootman et al., 2021] Rootman, J. M., Kryskow, M. J., Harvey, K., et al. (2021). Adults who microdose psychedelics report lower levels of trait anxiety and depression than non-microdosers. Scientific Reports, 11(1), 19028. Link
• [Carhart-Harris et al., 2018] Carhart-Harris, R. L., Roseman, L., Haijen, E., et al. (2018). Psychedelics and the essential importance of context. Journal of Psychopharmacology, 32(7), 725-731. Link
• [Roseman et al., 2019] Roseman, L., Haijen, E., Idialu-Ikato, K., et al. (2019). Emotional breakthrough and psychedelics: validation of the Emotional Breakthrough Inventory. Journal of Psychopharmacology, 33(9), 1076-1087. Link
• [Gukasyan et al., 2022] Gukasyan, N., Davis, A. K., Barrett, F. S., et al. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 79(1), 1-10. Link